{"schema_version":"secwatch.filing_event.v1","accession":"0000805928-24-000135","form_type":"8-K","ticker":"AXGN","cik":"0000805928","company_name":"Axogen, Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.058861+00:00","generated_at":"2026-05-30T04:07:26.649189+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Axogen Q3 revenue $48.6M (+18% YoY), adjusted net income $3.1M; BLA accepted by FDA","bullets":["Revenue $48.6M (+17.9% YoY); gross margin 74.9% vs 76.8% in prior year.","Net loss $1.9M ($0.04/shr) vs $4.1M ($0.10/shr); adjusted net income $3.1M ($0.07/shr).","Adjusted EBITDA $6.5M vs $2.4M in Q3 2023; cash $30.5M at quarter end.","FDA accepted BLA for Avance Nerve Graft under standard review; PDUFA date Sept 5, 2025; no advisory committee planned.","2024 revenue guidance reaffirmed $182M-$186M; expects high end of gross margin range and cumulative net cash flow positive."],"urls":{"canonical":"https://secwatch.observer/filing/0000805928-24-000135","json":"https://secwatch.observer/filing/0000805928-24-000135.json","markdown":"https://secwatch.observer/filing/0000805928-24-000135.md","text":"https://secwatch.observer/filing/0000805928-24-000135.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/805928/000080592824000135/0000805928-24-000135-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/805928/000080592824000135/axgn-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:07:26.649189+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}